Omios Bio is developing next-generation oncolytic virus therapy to treat solid tumors.
Cancer is a complex disease that requires complex therapies. Our patented platform technology uses a novel vaccinia virus to target cancer cell mutations in cell death programs offering exceptional cancer selectivity, and maximum cancer cell destruction.
Omios OV therapy overcomes limitations of current therapies by directly reaching metastases in a selective way, have an improved tolerability, no resistance, prevent relapse, and offer a durable effect. With a strong team, proven technology, and a large market opportunity, Omios is poised to revolutionize cancer treatment.
Company Details
- Employees
- 4
- Founded
- -
- Address
- Alameda, Ca 94501, Us
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Keywords
- oncolytic vaccine, oncolytic virus immunotherapy, cancer vaccine, Immunogenic Cell Death, Innate immune response, Cancer surveillance, systemic delivery, gene delivery.
- HQ
- Alameda, CA
Omios Biologics Questions
Omios Biologics's LinkedIn profile is https://www.linkedin.com/company/omios-biologics
Omios Biologics has
4 employees.
View email and phone details for 4
employees at Omios Biologics.
Omios Biologics's industry is
Biotechnology Research
Omios Biologics's top competitors are
Laribio Consulting,
Opentrons Labworks Inc.,
Nomic Bio,
Okomera,
Telomir Pharmaceuticals, Inc.,
Seegene Usa,
Omio,
Delve Therapeutics,
Nurix Therapeutics,
Entrada Therapeutics.
Omios Biologics's categories are Biotechnology Research
Omios Biologics's founding year is 2021
